
Hoth Therapeutics (HOTH) Stock Forecast & Price Target
Hoth Therapeutics (HOTH) Analyst Ratings
Bulls say
Hoth Therapeutics Inc. has demonstrated a robust potential for growth, as evidenced by the 100% efficacy seen in its Phase 2a CLEER-001 trial evaluating HT-001, which significantly reduced skin toxicity and enhanced quality of life for cancer patients undergoing treatment. The company is strategically positioned to facilitate clinical adoption through extensive real-world exposure of its therapies, which may strengthen its regulatory standing and enhance engagement with key stakeholders such as oncologists and patient advocacy groups. Furthermore, the promising results from open-label trials and case studies related to various therapies underscore Hoth's diverse pipeline addressing significant unmet medical needs, supporting a favorable outlook for its financial performance and market positioning.
Bears say
Hoth Therapeutics Inc. operates in a highly competitive and uncertain biopharmaceutical landscape, with several clinical trials ongoing that may not yield successful results, which raises concerns regarding the company's ability to advance its pipeline products. Financial data indicates high burn rates associated with research and development, creating potential liquidity issues if funding sources diminish or fail to meet expected needs. The company's reliance on unproven therapies for various conditions, coupled with the regulatory and market risks inherent in the sector, contributes to a challenging environment that could impede growth and profitability.
This aggregate rating is based on analysts' research of Hoth Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Hoth Therapeutics (HOTH) Analyst Forecast & Price Prediction
Start investing in Hoth Therapeutics (HOTH)
Order type
Buy in
Order amount
Est. shares
0 shares